Operational context includes a significant reduction in personnel and infrastructure costs following a 2025 restructuring to ...
Arvinas (NASDAQ:ARVN) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a strategy centered on advancing four Phase 1 clinical programs and preparing for ...
Q4 2025 earnings call recap: pipeline milestones, PROTAC FDA/PDUFA timeline, 2026 data catalysts, and cash runway—read now.
Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results